Episode Details
Back to Episodes144: Court Halts FDA Rule on Lab-Developed Tests: What It Means for Pathology
Episode 144
Published 10 months, 2 weeks ago
Description
Will FDA rules disrupt the way we diagnose diseases?
In this episode, I break down a seismic shift in lab medicine: a federal court has vacated the FDA’s controversial rule classifying lab-developed tests (LDTs) as medical devices. This change carries serious implications for innovation, digital pathology, AI-based diagnostics, and small labs across the U.S.
🎧 What You’ll Hear:
- What LDTs are and why they matter for rare diseases and personalized medicine
- Why the FDA rule sparked backlash from the pathology community
- What the court’s decision means for AI algorithms in digital pathology
- What’s next: Will Congress revive the VALID Act?
- How this affects labs, startups, and the future of diagnostic innovation
This podcast is packed with updates every pathology professional should know. 🔍